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ABSTRACT 
William S. Evans: The Effects of Prolonged Sitting on Arterial Stiffness and Circulating 
Angiogenic Cells in Healthy Adults 
 
 
To assess the effects of prolonged sitting on measures of arterial stiffness (AS) and 
circulating angiogenic cells (CAC), healthy but sedentary subjects completed 3 hours of sitting in 
a randomized crossover design with 10 calf raises every ten minutes (CALF) or a control 
condition (CON). Pulse wave velocity (PWV) and pulse wave analysis (PWA) and blood draws 
were performed pre and post to assess AS. CACs were isolated from venous blood for analysis. 
PWV significantly increased (Mean Difference [MD]0.30 m/s (0.46), p<0.01) and augmentation 
index (AIx) from PWA significantly decreased from pre-to post (MD=-9.14% (11.09), p<0.001). 
There was no significant change in CAC counts per 500,000 events or gene expression in either 
condition across time. In conclusion, aortic AS increases during sitting despite decreases in 
arterial wave reflection, and local changes observed previously with physical activity do not 
persist systemically.  
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CHAPTER I 
Introduction 
Emerging evidence suggests that sedentary behavior, including prolonged sitting, 
increases the risk for cardiovascular disease (CVD), the leading cause of death globally  [1-3]. 
While chronic associations are known, the underlying mechanism are unclear. Evidence from 
acute bouts of sitting suggest that prolonged sitting decreases blood flow and shear stress (SS) 
resulting in local endothelial dysfunction of the lower extremity, but these changes may be 
rescued by intermittent physical activity, and the systemic effects remain unclear [4-6].  
Optimally, assessing central changes in arterial stiffness (AS) such as aortic pulse wave velocity 
(PWV) and pulse wave analysis (PWA) would aid in understanding the adverse effects of sitting 
and the increased burden on the heart. While endothelial dysfunction increases during sitting, 
evidence also suggests that endothelial repair is attenuated in response to 10 days of physical 
inactivity as indicated by CFU-Hill counts[7]. CACs have paracrine function and contribute to 
repair of damaged vessels. However, the effects of acute inactivity on CAC number and function 
are not known. Therefore, to better understand functional changes in stiffness and the effects of 
sitting on vascular repair, PWV, PWA, and CAC count and function need to be examined before 
and after acute bouts of inactivity. Additionally, strategies to increase blood flow and shear stress 
need to be included to 1) provide additional mechanistic insight and 2) to develop other 
strategies to counteract the detrimental effects of sitting.  
2 
 
PWV is the gold standard approach for measuring aortic AS [8]. The aorta is directly 
proximal to the heart and its elasticity is responsible for dampening the speed and amplitude of 
retrograde pressure waves that increase the heart’s workload during systole [9]. Indeed, aortic 
PWV has particular relevance to CVD, with a 1 m/s increase in  PWV corresponding to a 14% 
and 15% increase in total CV events and CV mortality respectively, independent of traditional 
risk factors [10].  Pulse wave analysis (PWA) is also commonly used in junction with PWV to 
assess arterial wave reflection and central blood pressure, which has been shown as a better 
predictor of CVD than brachial blood pressure  [10, 11].  Together these measures provide 
valuable information relevant to cardiac burden and serve as clinically relevant markers of 
arterial stiffness. 
Acutely, endothelial dysfunction and AS may occur in response to decreased blood flow 
and shear stress. Indeed, it has been repeatedly shown that one bout of sitting reduces the NO 
dependent measure FMD in the lower leg suggesting endothelial dysfunction while local heating, 
exercise, and fidgeting have been shown to restore vascular health via increased shear stress [6, 
12, 13]. However, these changes only represent local changes in vascular health and do not 
provide central insight unlike PWV and augmentation index (AIx). Though changes in PWV and 
AIx are generally chronic and observed with aging, evidence does show a functional stiffening in 
response to NO antagonists [14]. In light of this evidence, simple perturbations such as fidgeting 
or greater stimuli such as calf raises should be generalizable to changes in central measures of 
AS such as PWV and AIx.  
In addition to changes in AS, shear stress has also been shown to indirectly affect CACs 
which are important for the repair of damaged endothelial cells. Specifically, CACs home to 
ischemic sites following damage, and secrete various angiogenic cytokines[15]. CACs are 
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CD34+ hematopoietic stem cells that were initially termed endothelial progenitor cells. In 
response to increased blood flow and shear stress, CACs increase expression of endothelial nitric 
oxide (eNOS) and NO production which mediates function of important angiogenic cytokines 
such as VEGF[18]. Additionally, shear stress dose dependently increases surface protein 
expression of VEGFR-2, VE-cadherin and Tie2 which are important for angiogenic capabilities 
and maintaining a restrictive endothelial barrier[19]. Furthermore, shear stress has been shown to 
augment homing and engraftment of CACs via increased signaling of CXCR4/JAK-2 pathway 
while also increasing expressing of CXCR4 in-vitro[19]. By affecting the secretion of VEGF and 
CXCR-4, shear stress may impact the homing, engraftment and angiogenic properties of CACs 
on damaged endothelium. Therefore, assessment of VEGF and CXCR-4 as gene targets on 
CACs is important, as they are likely impacted by decreased shear stress. 
Though blood flow and shear stress affect CACs, little is known regarding the effects of 
physical inactivity on CACs. Ten days of reduced physical inactivity reduced colony forming 
unit counts but did not affect circulating counts of CACs [7] but the acute effects of inactivity 
have yet to be determined. On the other hand, it is generally accepted that CAC counts and 
function increase with acute exercise [20-23]. If acute inactivity decreases CAC function, it begs 
the question if simple lower extremity muscular contractions (i.e. calf raises) may increase shear 
stress and CAC activity to offset the effects of sitting. Given their role in repair, regulation by 
blood flow and shear stress, and the paucity of evidence, it is important to establish the effects of 
sitting on both the quantity and quality of CACs. 
In light of the current evidence on sitting and vascular health, there remains a need to 
need to translate these findings into clear public health message and to understand mechanistic 
underpinnings. As such, addressing PWV, AIx and CACs during sitting provide as meaningful 
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variables that yield clinical and mechanistic relevance. Therefore, the purpose of this study is to 
understand the balance between damage and repair during prolonged sitting through assessing 1) 
changes in PWV and PWA, 2) CAC counts and gene expression and 3) if intermittent calf raises 
during prolonged sitting attenuates these changes. If prolonged sitting does increase AS and calf 
raises can prevent these changes, current public health recommendations and guidelines can be 
updated to prevent the deleterious effects of sitting. 
 
Research Questions 
1. Does PWV and PWA increase with 3 hours of prolonged sitting?  
2. Do CD34+ CAC counts decrease following 3 hours of prolonged sitting? 
3. Does gene expression of CACs change following 3 hours of prolonged sitting? 
4. Do intermittent calf raises prevent negative changes in AS or CACs? 
 
Research Hypothesis 
1. A 3-hour bout of prolonged sitting will increase PWV and AIx from PWA from pre to 
post testing. 
2. A 3-hour bout of prolonged sitting will decrease CAC counts. 
3. A 3-hour bout of prolonged sitting will decrease number of CD34+ CACs and expression 
of VEGF and CXCR-4. 
4. Intermittent calf raises during a 3-hour bout of prolonged sitting will prevent negative 
changes in PWV, AIx, and CD34+ CAC counts and function.  
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Assumptions 
1. Subjects followed pre-assessment guidelines. 
2. Pre-assessment guidelines were adequate to control for baseline changes in outcomes 
3. All subjects answered the medical history questionnaire and physical activity readiness 
questionnaire truthfully.  
Delimitations 
1. When able, women’s menstrual cycles were recorded and controlled. 
2. Repeated measures design was used to control for condition specific variability.  
3. All subjects had similar dietary intake prior to and during testing. 
4. All subjects were between the ages of 18-35. 
Limitations 
1. Blood flow induced shear stress was not directly measured during testing. 
2. Magnetic isolation of CD34 CACs did not result in 100% purity. 
Significance of Study 
 CACs have clinical significance given their relationship to the development of CVD. 
They function to both repair and potentially incorporate into damaged endothelium. Furthermore, 
they can decrease following sedentary behavior and with other risk factors such as smoking and 
hypertension. Their relationship to emerging risk factors such as central measures of AS may 
further explain the etiology of cardiovascular disease and the underlying mechanisms. Moreover, 
because prolonged sitting is a  precursors to and is associated with increased risk of CVD, a 
better understanding of the balance between damage and repair will help with treatment and 
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prescription. Lastly, the results of this study may lead to simple public health initiatives during 
the work day, such as calf raises, to prevent CVD and lower the economic burden on health care. 
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Chapter II 
Literature Review 
 This review is divided into the following sections: 1) Mechanisms of Inactivity, Sitting, 
and Vascular Physiology 2) AS and Inactivity 3) AS and Endothelial Dysfunction 4) Progenitor 
Cells and eNOS/NO 5) Physical Activity and CACs. 
 
Section 1: Mechanisms of Inactivity, Sitting, and Vascular physiology 
 The effects of inactivity are well documented in current literature. Beginning with the 
London bus study, study of physical activity and inactivity, has progressed [24]. Through this 
evidence, sedentary behavior is now considered a risk factor for the development of 
cardiovascular disease (CVD) according to the American College of Sports Medicine [25]. 
However, the precise mechanisms governing these changes are not concrete, and recent evidence 
suggests the type of inactivity seems to matter. 
1.1 Animal Models 
Mechanistically, studies of physical inactivity utilizing animal models have greatly added 
to our body of knowledge. These studies have shown that vascular health, assessed by ability to 
produce proteins or respond to drug and mechanical stimuli, relies on changes in blood flow. 
Specifically, animal models utilizing in-vitro flow testing of arterial tissue and rat hind-limb 
suspension provide evidence suggesting a role of increased blood flow (BF) and shear stress, the 
frictional force of blood. In the rat hindlimb-unloading model, the rat is suspended by the tail to 
inhibit use of the hindlimbs and promote use of the forelimbs. Results from this model show a 
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decrease in blood flow due to inactivity and the absence of gravity result in a decrease in the 
expression of eNOS mRNA as well as protein expression, suggesting a decreased ability to 
produce NO [26]. This model also showed a decrease in the ability to vasodilate in response to 
acetylcholine and differing flow patterns, functionally supporting the hypothesis that the absence 
of flow decreases NO availability and sensitivity. Further testing these mechanisms, studies used 
acetylcholine and NO, which induces vasodilation, and inhibitors of NO, thus decreasing 
vasodilation, on arteries from hind-limb unloaded rats. Similar to previous studies, these findings 
indicated a decreased vasodilatory response to acetylcholine in hindlimb unloaded rats [27]. 
Furthermore, administration of eNOS and NO inhibitors reduced acetylcholine vasodilation by 
40% in control rats, but completely inhibited vasodilation in hindlimb unloaded rats [28]. 
Together, these findings showed attenuated endothelium-dependent vasodilation with a particular 
emphasis on the NO pathways, thus providing evidence that shear stress modulates NO pathways 
and potentially vascular health. In addition to changes in vasodilatory function, vasoconstriction 
is also inhibited in response to hind-limb unloading [29]. In response to vasoconstrictors such as 
norepinephrine and KCl after hindlimb unloading, gastrocnemius arteries showed decreased 
ability to vasoconstrict and maintain myogenic tone at high pressures, indicating a loss of 
vascular sensitivity and strength. These studies also found that the changes in vasodilation and 
vasoconstriction may be a result of decreased thickness of smooth muscles and subsequently loss 
of motor strength.  
To more specifically test mechanisms necessitating the presence of shear stress, soleus 
muscle feed arteries were isolated and introduced to various levels of flow [30]. Results from this 
study showed that arteries dose dependently produce eNOS in response to various levels of flow. 
Furthermore, pre-treatment with high-flow resulted in a significantly greater vasodilatory 
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response to acetylcholine than no-flow. Again, administration of NOS inhibitors abolished 
vasodilation. Together, these findings suggest that blood flow induced transmural pressure and 
shear stress are important for the maintenance of endothelial function, which depends on release 
of eNOS and NO and subsequently sensitivity to NO.  
 
1.2 Human Models 
In human models of decreased activity, spinal cord injury patients (SCI) and bed rest 
have been used. These studies compared SCI and healthy men for differences in endothelial 
function via flow mediated dilation (FMD), a test of endothelial dependent response to shear 
stress, and in response to nitroglycerin spray, a test of endothelial independent sensitivity to NO 
[31]. SCI showed a significantly enhanced FMD response in the superficial femoral artery, but 
no significant differences were found in the brachial artery. When correcting for the amount of 
shear rate stimulus (FMD is dose dependent), there was no significant difference between SFA 
arteries of SCI and control, but control had significantly greater increase in brachial artery FMD. 
The response to nitroglycerin spray was not significantly different between the conditions, 
suggesting that these patients had preserved vascular function, even in inactive legs. Similar to 
this study, 52 days of deconditioning by bed rest resulted in an increased sensitivity to nitric 
oxide in the SFA as measured by dilation in response to nitroglycerin and FMD [32]. This study 
did find a reduction in the diameter of conduit arteries. Further studies assessing 60 days of bed 
rest found decreases in plasma volume, increases in isovolumic relaxation time and myocardial 
performance index, suggesting a decrease in cardiac function [33]. These studies found decreases 
in anterior tibial artery intimal-medial thickness and a trend towards decreased orthostatic 
tolerance following 60 days of bed rest. Additionally, subjects in this study showed no 
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significant difference in response to sublingual nitroglycerin spray, and a significant increase in 
FMD of the anterior tibial artery. Although these seem different, it was proposed that the 
decrease in smooth muscle cross sectional area would increase the diffusion of NO into to the 
muscle to induce vasodilation, while the NO-sGC signal transduction cascade in smooth muscle 
(tested via nitroglycerin spray) was unlikely, as there is no systemic change in endothelium-
independent NO dilation. Although these studies report somewhat surprising findings regarding 
the mechanisms behind changes in changes in endothelial function with inactivity, evidence 
remains that SCI and inactivity increases risk for CVD, suggesting confounding variables such as 
changes in smooth muscle volume may partially explain these findings. 
Another possible explanation of these findings was proposed by a study evaluating 
autonomic nervous system function [34]. In this study, heart rate variability (HRV) and blood 
pressure variability were monitored in SCI and CON. Using spectral analysis of R to R interval, 
cross-spectral analyses of low-frequency spectra, this study showed that SCI had reduced 
sympathetic drive to the heart and vasculature, increased baroreflex delta in cervical SCI and 
reduced cardiac vagal tone in thoracic SCI subjects. Together, these findings were used to show 
that autonomic nervous system dysfunction may partially explain changes in cardiovascular 
health.  
1.3 Prolonged Sitting 
Although the effects of bed rest and SCI on vascular physiology is less congruent, the 
effects of physical inactivity such as sitting is clearer. In terms of risk, increased sitting time is 
associated with increased risk of cardiovascular disease and all- cause mortality. A 15 year 
prospective study included 17,000 participants and asked them to subjectively report their sitting 
time [35]. The findings of this study indicated that individuals who reported sitting almost none 
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of the time to almost all of the time were progressively more likely to die from cardiovascular 
disease even after adjustment for other variables such as smoking, age, sex, and body mass 
index. This study reported hazard ratios ranging from 1.00 when active to 1.54 when sitting 
almost all of the time [35]. Although this study clearly established the connection between sitting 
and cardiovascular disease. Sitting also significantly increases the risk of all-cause mortality 
(HR, 1.220), diabetes (HR, 1.910), cardiovascular disease incidents (HR, 1.143), and cancer 
incidence (HR, 1.130) independent of exercise [36]. 
In light of these findings, studies aimed at explaining the specific mechanisms were 
conducted. Because the role of blood flow induced shear stress regulated various measures of 
vascular health at the micro and macrovascular scale, models of sitting were developed to assess 
changes in blood flow, shear stress, and endothelial macro and microvascular function. Initially, 
these models aimed to assess hemodynamic changes in both the brachial and femoral arteries 
[37]. Similar to animal models, these studies assessed endothelial function via changes in Flow 
Mediated Dilation. In review, FMD is the gold standard for measuring endothelial function and 
is an indication of endothelial cells’ ability to autoregulate in response to stresses by releasing 
NO and other vasodilators to maintain blood flow. The first of these studies assessed changes in 
SFA and BA FMD and flow patterns over 3 hours of sitting [37]. This study showed that sitting 
resulted in impaired shear patterns associated with endothelial dysfunction in both the SFA and 
BA. However, the SFA showed decreases in FMD, but the BA did not. This study suggested that 
leg vascular function was primarily impaired during sitting as a result of changes in shear stress. 
A similar design and study was performed following this study; however, subjects walked at the 
30 minute, 1 hour and 30 minute, and 2 hour and 30 minute time point [38]. Similar to the 
previous study, sitting reduced measures of FMD and mean shear rate and antegrade shear rate; 
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however, walking resulted in no significant declines in these measures. These findings illustrated 
that macrovascular function was clearly impaired during sitting and was likely regulating by 
changes in blood flow and shear stress.  
To test changes in microvascular function, as the level of artery can differ in functional 
responses to shear stress, a similar design was used. Subjects again sat for 6 hours while 
measures of FMD and reactive hyperemia (a measure of microvascular reactivity) in the 
popliteal artery and BA were collected [5, 39]. This study found that sitting resulted in 
significant decreases in popliteal artery FMD and reactive hyperemia; conversely, BA FMD was 
unchanged after sitting while microvascular function was impaired. Additionally, walking post 
sitting restored measures of FMD and reactive hyperemia. 
Several follow-up studies by the same condition used only 3 hours of sitting while using 
local heating or fidgeting one leg to assess the role of blood flow and shear stress [6, 13]. This 
condition found that local heating and fidgeting restored measures of blood flow, shear stress, 
and FMD, while the control leg showed significant decreases in FMD. These findings were 
consistent with hypotheses that sitting induced leg endothelial dysfunction via reductions in 
blood flow and shear stress, and that simple interventions could be used to mitigate these 
findings.  
 
Section 2. AS and Inactivity 
Although endothelial dysfunction plays a large role in the development of atherosclerosis, 
other vascular measures such as AS have associations with CVD [40]. Additionally, methods of 
measuring AS require less expertise for accurate results, and are highly reproducible. The 
specific mechanisms resulting in AS are still studied, but a link between characteristics of 
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endothelial dysfunction, such as decreased bioavailability of NO, and AS exist. Thus, this 
relationship may partially explain the underlying mechanisms by which sitting may result in AS 
and subsequently CVD.  
AS is a measure of arterial compliance, aortic pulse wave velocity is the gold standard for 
measuring arterial compliance [8]. A recent study assessed aortic pulse wave velocity (PWV) in 
2835 subjects who were apparently healthy [40]. Hazard ratios for development of coronary 
heart disease for subjects in the second and third tertile were 1.72 and 2.45, respectively. 
Additionally, these hazard ratios did not significantly differ after adjustment for cardiovascular 
risk factors. This study poses a strong prognostic value of PWV.  
Additionally, a meta analyses including over 15,000 subjects found that increased PWV 
resulted in an increased risk clinical events including all-cause mortality, cardiovascular events, 
and cancer. [10]This increased in a step wise fashion. These studies established a clear 
relationship between increased PWV and disease.  
Prolonged sitting and AS increases the risk for developing CVD and other non-
communicable disease. A study of 1241 Brazilian adults 30 years of age showed a positive 
association between sedentary time measured by accelerometry and PWV [1]. Furthermore, a 
negative association was seen between individuals engaging in more PA and PWV. In summary, 
these findings indicate that AS could be altered by physical inactivity or vis versa. 
 
Section 3. AS and Endothelial Dysfunction 
A link between physical inactivity such as prolonged sitting and endothelial dysfunction 
is quite clear. Additionally, these changes are associated with hemodynamic changes. The results 
of these hemodynamic changes may be regulating changes in AS. 
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As aforementioned, endothelial dysfunction is characterized by a decrease in the release 
of NO. Decreases in the bioavailability of NO can be observed in response to decreases in blood 
flow and  shear stress. Studies have assessed the role of NO and shear stress on AS, and the two 
appear to be interrelated[30, 41]. For example, Kinlay et al. injected various concentrations of 
Nitroglycerin, an exogenous form of NO, and L-NMMA an inhibitor of NO and measured 
changes in PWV[42]. L-NNMA resulted in increased measures of PWV, while nitroglycerin had 
the opposite effects. Another study administered concentrations of acetylcholine and glyceryl 
trinitrate, both characterized as NO donors, and observed significant decreases in PWV[43]. 
Furthermore, this study illustrated that co-injection of acetylcholine and L-NMMA, an NO 
inhibitor, resulted in no significant difference in elasticity. Of note, these changes occurred 
independent of changes in mean arterial pressure (MAP). This is significant given the fact that 
increases in vasoconstriction would increase MAP thus increasing PWV. 
These studies were all local in nature, i.e. use direct arterial injection of NO directly into 
arteries where elasticity was measured. Systemic administration of NO and inhibitors has 
produced varying results. In healthy humans, radial arterial pulse pressure waves forms were 
monitored with a tonometer device to monitor reflected waves and compliance.[14] In this study, 
intravenous injection of NO agonist and L-NAME, a stereospecific inhibitor of NOS produced. 
In this study infusion of L-NAME decreased small artery compliance but had the opposite effect 
on systemic vascular resistance. Sublingual glycerol trinitrate decreased both large and small 
artery compliance. These studies were conducted in arteries primarily characterized as muscular 
arteries. With age, these arteries have a smaller decrease in arterial compliance as opposed to the 
elastic aorta.  
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 In a similar design, this was tested. L-NMMA was introduced with norepinephrine and 
dobutamine to help control for potential changes in stiffness as a result of pressure [44]. 
Norepinephrine increases pressure through an increases peripheral resistance, but dobutamine is 
a positive inotrope that vasodilates smooth muscle. Despite their differing mechanism of action, 
both of these drugs increase MAP. In this study, increases in PWV and AIx were observed 
during injection of L-NMMA, suggesting that inhibition of NO increases stiffness. However, 
these effects were similar to those observed during injection of norepinephrine and dobutamine. 
Therefore, this study suggested that changes in stiffness were not actually a result of compliance, 
but instead a result of changes in MAP.  
Notably, elasticity in relation to NO production can change as a function of exercise. A 
rat study using 8-weeks of aerobic exercise illustrated increases in aortic rings vasorelaxation 
[45]. This study dissected thoracic aortic rings and tested NO production along with aortic 
tension in response to methacholine, an endothelium dependent agonist of NO. This study 
established that trained rats had increased production of NO and increased maximum relaxation, 
suggesting again that NO’s effect on vasomotor tone of smooth muscles can be modified by 
physical activity and is partially dependent on NO.  
However, these studies primarily assessed changes in stiffness using either drug 
interventions or chronic training adaptation. Additionally, prior studies assessing stiffness with 
exercise or sedentary behavior have been cross sectional or longitudinal in nature [1, 10, 40]. 
However, it has been shown that NO dependent measures of endothelial function such as FMD 
are decreased following only an acute bout of sitting [5, 6, 12, 13, 37]. Therefore, it is possible 
that increases in stiffness, and thus cardiac afterload, could result following sitting. These 
increases in stiffness may likely occur as a result of decreased blood flow and shear stress as 
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blood pools in the legs and systemic flow decreases [4, 38]. Interestingly, some studies have 
proposed that stiffness may actually increase endothelial dysfunction, suggesting a cyclic 
relationship [46]. Although local changes have clearly been assessed, it is unclear whether 
central measures of elastic arteries such as the aorta decrease. 
Section 4. Progenitor Cells and eNOS/NO 
Endothelial Progenitor Cells (EPC) are a bone marrow derived stem-cell capable with 
angiogenic capabilities. EPC are now more broadly recognized as circulating angiogenic cells 
(CAC). Similar to conventional endothelial cells (EC), this cell type produces and is regulated by 
shear stress, eNOS and NO. Although much debate surrounds their specific function, origin, and 
phenotyping, these cells are important for repair and generation of endothelial cells, and counts 
and assays are clinically relevant in regard to the development of CVD and CV related events.  
EPCs were initially identified by Asahara et al. because of prior evidence suggesting 
HSC circulated in the periphery.  By staining for CD34+, an HSC marker and Flk-1, a receptor 
for vascular endothelial growth factor (VEGF) that is expressed by endothelial cells, this group 
was able to identify and isolate EPCs from peripheral blood. Further analyses showed that these 
cells uptake acetylated low density lipo-protein , which is specifically uptaken by endothelial 
cells [47]. Additionally, fluorescent labeling with the dye DiI, showed specifically which cells 
were capable of differentiation and producing spindle shaped cells in-vitro. Lastly, this group 
was able to show that specifically through various markers and prior uptake of DiI labeled 
acetylated low density lipo-protein that these cells could incorporate into ischemic damaged 
tissue to produce blood vessels. Additionally, these cells showed positive immunoblotting for 
eNOS and the endothelial marker CD31. 
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However, this cell population has some drawbacks which have been extensively covered 
in a review by Yoder 2013. [48] Briefly, EPCs characterized by various clinical are most likely 
HSCs at various stages of development during their isolation. Additionally, these cells may also 
be monocytes and macrophages that release proangiogenic cytokines, thus contributing to the 
angiogenic properties. Therefore, these cells are more recently termed Circulating Angiogenic 
Cells (CAC) to describe a heterogenous cell population labeled with traditional markers, such as 
different combinations of CD34, VEGFR2, and CD133, capable of promoting angiogenesis and 
neovascularization either directly or indirectly.  
Specifically, the use of mouse models where the SFA is cut, thus inhibiting blood flow, 
have been used to test their neovascular capabilities. [49] Asahara et al. also included a plethora 
of other tests utilizing a mouse model and staining for EPCs to show that EPCs appear to recruit 
to capillaries among skeletal myocytes after ischemic damage post myocardial infarction [16]. 
Additionally, it was shown that EPC help reestablish blood flow after cutting of the SFA.  
Similar models assessing their regenerative capabilities expounded on these findings with 
a specific emphasis on the role of eNOS and NO. NO is produced in response to shear stress via 
the Akt pathway by endothelial cells, and CACs as they express similar membrane proteins [19, 
41]. NO is anti-atherosclerotic in nature as it prevents leukocyte adhesion and migration into the 
sub endothelial space, the proliferation of smooth muscle cells, and NO operate as an anti-
oxidant and prevent platelet aggregation[50-54]. Mice deficient of the eNOS creating gene 
showed an inability to mobilize in response to VEGF, an autocrine factor released by EPCs, 
additionally, these mice showed increased mortality after myelosuppression. However, when 
EPCs from wild-type mice were administered, the neovascular effects were restored in a rat 
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hind-limb ischemia model. Bone marrow transplantation did not have these effects suggesting 
that eNOS plays a role in proper recruitment and development of EPCs during hematopoiesis. 
Furthermore, CACs migration is regulated by eNOS/NO. In healthy subjects, the ability 
of CACs to migrate in response to VEGF was impaired by NOS inhibitors, while addition of NO 
donors resulted in increased movement and migration in response to VEGF[55]. Additionally, 
CAD patients showed no expression of eNOS in comparison to healthy participants, and CACs 
from CAD patients showed impaired response to VEGF that was restored when NO donors were 
administered. Patients with CAD also showed decreased measures of NO dependent FMD and 
concentration of plasma NO. Together these findings showed that CACs function is dependent 
on proper expression of eNOS and subsequently NO. Furthermore, patients with CAD have 
impaired CAC responses and eNOS expression suggesting that absence of NO may not only 
increase development of atherosclerosis but may also impair repair of endothelial cells. These 
results are not surprising given the association between presence of CVD and decreased count 
and migratory ability of CACs [56]. 
Lastly, a study utilizing a viral vector, AVE9488, to overexpress the eNOS protein, 
showed significant promise [57]. This study illustrated that after MI, rats treated with AVE9488 
showed various improvements in heart function and molecular changes. Mice overexpressing 
eNOS prevented the decreases in seen in CACs post MI, improved LV function, improved FMD 
results, increased eNOS protein expression, and decreased presence of the superoxide anion. 
Clearly, these results suggest a significance of eNOS post infarction, and these changes may 
possibly be through the function and maintenance of CACs.  
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Section 5. Physical Activity and CACs 
 Multiple relationships exist between inactivity, endothelial dysfunction and disease. 
Additionally, similar links exist between CACs, endothelial dysfunction and disease. Therefore, 
some evidence exists relating changes in CACs to both physical activity and inactivity.  
 CACs do respond to physical activity. Volunteer subjects (n=22) performed exercise to 
max intensity, and pre and post blood draws were compared. The markers used in this study were 
VE-Cadherin and CD133. The number of CACs and EPCs increased immediately post exercise 
by over 2.5-fold in CACs and 4-fold in EPCs. However, secretion of angiogenic cytokines 
VEGF, GM-CSF, HGH, and G-CDF were not significantly different in pre to post measures 
from CACs.  
 However, a more recent study using a more comprehensive anti-body panel did not see as 
robust changes. This study was designed to assess the kinetics of CAC and EPC, so multiple time 
points during exercise were examined [58]. CD34+ CACs were significantly increased at 20 
minutes and 40 minutes of training compared to pre-test measures. Additionally, HSPCs and 
HSCs labeled as CD34+/CD45low and CD34+/CD45low/CD38-, respectively, were 
significantly increased at 20 minutes during exercise compared to 60 minutes post exercise, 
suggesting a biphasic response. This data indicated slightly different results most likely due to 
the use of different markers, and different intensities.  
 Interestingly, exercise training appears elicit increases in EPCs and CACs, and these 
changes can even occur in diseased populations such as CAD[59]. CAD patients showed 
decreased migratory capacity at baseline but was improved post exercise. Additionally, these 
patients showed improved FMD measures along with a 77% increase in migratory capacity of 
CACs. Interestingly, changes in CACs from pre to post exercise were not observed post training, 
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suggesting that training may reduce sensitivity of CACs to stress. Lastly, EPC counts were 
significantly greater post training in CAD patients. These findings suggest that repeated bouts of 
exercise may initially increase measures of CAC to induce repair, which is subsequently 
reflected by changes in FMD and improved functionality of endothelial cells.  
 In addition to the effects of exercise training, studies assessing the effects of training 
status and detraining on behavior of CACs has provided insight into their responses [60]. 
Comparisons between highly active endurance trained men and healthy low-active men showed 
no significant difference between baseline values of CACs or EPC.  However, following 10 days 
of detraining, highly active men showed significant decreases in CACs, and a positive 
correlation between the change EPCs and reactive hyperemia. Additionally, the percent change 
in EPCs and EPC senescence was correlated with changes in total oxidative capacity. These 
results introduced new and interesting perspectives with regards to inactivity and the possible 
underlying mechanism, i.e. oxidative stress and nitric oxide.  
 A follow-up study using very similar methods further assessed the role of NO and 
oxidative stress[20]. This study utilized a similar design in apparently healthy men and evaluated 
changes in CAC counts, CFU-CACs, intracellular NO, related gene expression of NO and 
oxidative stress. This study found significant decreases in the number of CFU CACs along with 
production of intracellular NO. However, this study did not observe any significant decreases in 
genes related to NO or oxidative stress. Additionally, this study did not observe any significant 
differences in CD34+ CACs. In light of previous findings, this study suggested that changes in 
CACs is population dependent. 
 Finally, work by Dr. Landers-Ramos has further evaluated the effects of training and 
detraining on various subpopulations of CACs, primarily CD34+ and CD34-/CD31+ cells [61]. 
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In these studies, apparently healthy active, inactive, and endurance trained subjects were 
assessed. Again, no differences in redox status was found in any group across either cell type. 
Media from CD34+ and CD34-/CD31+ CACs of endurance trained individuals and inactive 
individuals’ cells was added to human umbilical vein endothelial cells. In inactive participants, 
endothelial cells produced vessels that were shorter and less complex. Furthermore, the changes 
in tube formation was attributed to two specific proteins and their respective ratios.  
 These findings establish relationships between CACs and physical activity. Although the 
role of NO and other proteins appears insignificant, it is likely that NO still plays a role in their 
function with activity. These studies have been observed either due to training status or 
prolonged physical inactivity, with only one study reporting sedentary time trending towards a 
significant difference [7]. Yet, significant changes in hemodynamics and NO dependent FMD 
are observed after only one bout of prolonged sitting, while walking, fidgeting, and prior aerobic 
exercise were able to mitigate these findings altogether [12, 38, 62]. Therefore, we propose that 
changes in hemodynamics associated with entering the lab or prior training status may have 
played a role in inconclusive findings. Regardless, the effects of an acute bout of sitting may 
decrease counts or function of CAC, and these changes should be evaluated to better understand 
and treat the effects of prolonged sitting. 
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Chapter III 
Methods 
Subjects 
Five males and 15 females, ages 18-35 were recruited. All subjects were sedentary, 
according to the American College of Sports Medicine Guidelines. Exclusion criteria included: 
any known cardio-metabolic disorders, pregnant women, smoking, physically active more than 
150 minutes of moderate physical activity per week, and any medication known to affect 
cardiovascular health. Because fluctuations in estrogen or testosterone can affect cardiovascular 
measures, women were tested within 1-10 days of their menstrual cycle. The study was approved 
by the University of North Carolina at Chapel Hill’s institutional review board. Subjects signed 
an informed consent form prior to participate in the study.  
 
Study Design and Pilot Testing 
The design was a randomized crossover design with two experimental conditions (control 
[CON] and CALF raises [CALF]) preceded by a familiarization session (Figure 1). All testing 
took place in the Applied Physiology Laboratory at the University of North Carolina. Prior to 
arrival for testing, participants filled out a medical history questionnaire, physical activity 
readiness questionnaire (PAR-Q) and informed consent. Using online randomization software 
(www.randomizer.org) participants were randomized into either CON or CALF intervention for 
first visit. 
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Because calf raises have not been previously shown to restore leg vascular function, pilot 
testing was performed. To verify that calf raises were sufficient to increase blood flow and shear 
stress, a one hour sitting protocol with single leg calf raises was administered. Subjects rested in 
the supine position for 20 minutes and were then seated for one hour. During sitting subjects 
performed 10 calf raises on one leg every 10 minutes. An ultrasound probe was placed on the 
femoral artery to measure blood flow, antegrade shear stress, retrograde shear stress and 
oscillating shear stress on both legs. Measurements were collected for five minutes at 5, 15, 25, 
35, 45, and 55 minutes on each leg.  
 
 
 
 
Figure 1. Example of subject visits in randomized crossover design. Subjects were familiarized 
and randomized into either CALF or CON on two subsequent visits. All testing was completed 
within two weeks of visit 1. 
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Familiarization 
Subjects reported to the laboratory to review documentation and to sign the informed 
consent. Participants were placed in a chair and chair height was selected to place feet flat on 
ground and thigh to calf angle at approximately 90 degrees to standardize within and between 
trials. During this time, participants practiced several sets of 10 calf raises. After reviewing pre-
test guidelines, subjects were given a supplement bar (Pure Protein, Bohemia, NY, USA) to 
consume 2 hours before their first visit to prevent risk of hypoglycemia. 
Visit 1 & 2 
 Subjects arrived after an overnight fast between 0600 and 1000 and one to seven days 
following the familiarization visit. After reviewing pretest guidelines, participants were fitted for 
an accelerometer (wActiSleep +; ActiGraph LLC, Fort Walton Beach, FL) on their right ankle to 
covary for spontaneous movement, and a 3-lead electrocardiogram for HRV analysis (HRV Add-
On For LabChart, PowerLab 4/26; ADInstruments, Colorado Springs, CO, USA). Subjects then 
rested in the supine position for 20 minutes for accurate resting baseline measures. PWV and 
PWA were collected in triplicate followed by a venous blood draw.  
Following the blood draw, subjects were then transferred to a seated upright position in 
the same chair with settings recorded from familiarization. Subjects were given 500 mL of water 
and began sitting while watching home improvement show. In both conditions, CALF and CON, 
subjects were notified at 10 minute intervals, but only CALF performed 10 calf raises to a 
metronome (Pro Metronome Xiao Yixiang ©2016 EUMLab, Xanin Tech) set to 20 beats/minute 
at 10 minute intervals to activate the muscle pump. To understand changes in wave reflection 
during sitting, PWA was collected at 10, 90, and 170 minutes of sitting.  
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After 180 minutes, subjects were carefully moved back to the supine position and rested 
for 20 minutes followed by measures of PWV, PWA and a final blood draw (36 mL). Blood 
could not be collected for pre to post CAC comparison on two subjects, and there was 
insufficient blood volume from four subjects to complete CAC gene expression.   
 
 
Arterial Stiffness 
During rest, a blood pressure cuff was placed on the non-dominant leg for calculation of 
PWV and on the non-dominant arm for PWA. To determine PWV, a path length from the carotid 
artery to the femoral artery is needed.  Path length for PWV was measured by palpating for the 
carotid artery and marking the neck. The carotid notch was identified superior to the meeting of 
the clavicles and sternum. A cuff was then placed on the non-dominant leg so the top of cuff 
aligned near the femoral artery. Distance from the carotid artery to sternal notch, the top of cuff 
to sternal notch and from the top of cuff to femoral crease was recorded and entered into 
Sphygmocor software for PWV calculation. The top edge of the cuff was marked to ensure 
identical placement during post sitting measures. A tonometer was placed on the neck, and PWV 
was collected in triplicate when wave form and quality control were recognized by the 
Sphygmocor. 
For PWA, a blood pressure cuff was placed on the arm and Sphygmocor device to 
calculate central pressures and arterial wave reflection. PWA was recorded in triplicate on the 
non-dominant arm.   
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HRV 
 HRV was collected to give indices of the autonomic nervous system, as it has been 
shown to affect vascular parameters [34, 63].  For analysis, 5-minute of ECG data was pooled 
and ectopic beats were excluded. Spectral analysis of the R-R interval was used to assess 
contribution of the parasympathetic nervous system. The root mean square of the standard 
deviation of R to R intervals was also recorded as an indication of autonomic nervous system 
function. 
 
Peripheral Blood Mononuclear Cells (PBMC) Isolation and Immunofluorescence Labeling 
Immediately following the final draw, peripheral bound mononuclear cells (PBMCs) 
were isolated using SepMateTM-50 (Stemcell, Vancouver, BC Canada) as specified by the 
manufacture. CAC cell phenotyping was determined using direct immunofluorescence labeling 
of cell surface markers with mouse anti-human monoclonal antibodies. Cells were stained with 
Live-Dead Zombie Dye (Green) and incubated at 4°C for 15 minutes in the dark. Cells were then 
incubated with pre-titrated antibodies [CD3 (APC-Cy7); CD45 (PerCP-Cy5.5); VEGFR-2 (PE); 
CD34 (BV421); CD31 (APC); Biolegend, San Diego, CA, USA)] and FCr blocker (Miltenyl 
Biotec, Auburn, CA, USA) in a total volume of 100µL of cell staining buffer (Biolegend, San 
Diego, CA, USA). Cells were washed to remove excess antibody and fixed in 2% 
paraformaldehyde prior to being suspended in 200 µL of cell staining buffer for flow cytometry 
analysis. Appropriate isotype and fluorescence minus one (FMO) controls were run. Cells were 
analyzed using an Attune NXt flow cytometer (BD Biosciences, CA USA) and FCS Express (De 
Novo Software, Glendale, CA). 
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CD34+Isolation and Gene Analysis 
 Remaining PBMCs were resuspended at a density of 2*108 cells / mL (RoboSep Buffer, 
Stemcell, Vancouver, BC Canada). Anti-CD34 antibodies were added at a concentration of 
100µL/mL and incubated at room temperature for 15 minutes. After incubation, magnetic 
particles were added at a concentration of 50µL/mL and incubated for 10 more minutes at room 
temperature. Cells were then placed in the EasySep™ Magnet (Stemcell, Vancouver, BC 
Canada) and incubated for five minutes at RT. The negative fraction was decanted and the 
remaining positive fraction was washed with 1mL of RoboSep Buffer and topped up to 2.5mL, 
and this was repeated four more times. Pilot testing was peformed prior to starting the 
experiments to determine the optimal balance between sufficient cell yield and purity (refer to 
appendix?). Following washes, cells were resuspended in 1 mL of TRIzol (Invitrogen, Carlsbad, 
CA, USA) and placed in -80°C freezer until further analysis.  
Gene analysis was performed according to previously published results [64]. Briefly, 
RNA was quantified using a spectrophotometer (BioTek H1 Synergy Hybrid Reader, BioTek 
Instruments Inc.) and reverse transcriptase was used to generate cDNA (Life Technologies, 
Grand Island, N.Y., USA). Quantitative RT-PCR was completed using a Applied BioSystems 
7300 Real-Time PCR System. Purchased from IDT (Coralville, Iowa, USA), primers were 
optimized for concentrations producing efficacy of >90%. Reactions were performed in duplicate 
on a 96-well plate and contained iTaq Universal Probes Supermix (Bio-rad, Hercules, Calif., 
USA), respective primer probe, and the cDNA template. The PCR conditions used were as 
follows: 95 °C for 3 min, followed by 50 cycles of 95 °C for 15 s, and 60 °C for 45 s. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primers were used as control to verify 
cycle thresholds (CTs) were not different across time in the present study. mRNA expression 
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values are presented as 2−ΔCT, where ΔCT is the CT of the target gene minus GAPDH control 
for each condition 
Power Calculation 
 Sample size calculations were based on the primary central vascular health outcome, 
aortic pulse wave velocity (PWV). While the effects of prolonged sitting on central vascular 
health have not been investigated, previous studies have reported that prolonged sitting reduces 
leg vascular health (endothelial function) between 57-80%[6]. For the current study, we opted to 
sample based on a conservative change score of 1 m/s. We also opted to use a conservative 
typical error of 1 m/s. Using magnitude-based inference, to estimate the sample size required to 
detect the smallest detrimental (or beneficial) effect in a cross-over study, with the maximum 
chances of a type 1 and 2 error set at 5% (i.e. very unlikely), approximately twelve participants 
were required. Oversampling was performed to account for potential incomplete cases and the 
exploratory nature of sitting on CAC number and function. 
Statistical Analyses  
Data collected was analyzed with SPSS Statistics version 21.0 (SPSS, IN., Chicaogo, IL 
USA). The α level was set a priori for all statistical procedures at α=0.05. Descriptive statistics 
will be used to summarize subject characteristics. Changes in PWA were compared in the supine 
and seated position respectively and changes over time are represented as mean difference and 
standard deviation (MD(SD)). The effect size (ES) is represented as partial eta squared and was 
calculated by SPSS software during ANOVA analyses. A one-way, repeated measures ANOVA 
was used to compare results from CAC counts, PWV, PWA and gene expression between 
baseline and post testing after exercise, respectively. An effect size of <0.2 was deemed trivial, 
0.2-0.4 small, 0.4-0.6 moderate, and > 0.6 large. 
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Chapter IV 
Results 
Participants Information 
Seventy percent of the recruited participants were women and 21.7 (2.9) years old. The 
average BMI was 25.7 (5.3) kg/m2. 
Arterial Stiffness 
There was no significant interaction for PWV or PWA. PWV significantly increased 
from pre to post [0.30 m/s (0.46), p<0.01 ES=0.532] following sitting (Figure 2A). During sitting 
AIx significantly decreased for both conditions from 10 to 90 and stayed depressed at 180 [-9.64 
% (11.78), p<0.01] and [-8.26 % (13.91), p=0.01] (Figure 2B). In the supine position, AIx from 
PWA significantly decreased from pre to post in both conditions [-9.14 % (11.09), p<0.001]. 
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HRV 
Heart rate significantly decreased from pre to post in the supine position (Table 2. p=0.012) but 
did not significantly change during sitting (Table 3). RMSSD used to calculate HRV 
significantly increased during sitting from 10 to 180 minutes [10.3 (25.19), p=0.014 ES=0.236]. 
The low frequency (LF) range of HRV tended to change across time (p=0.056) with a trend for 
LF to increase from 10 to 90 minutes [7.4 (12.18), p=0.057] and the high frequency range (HF) 
of HRV significantly decreased during sitting (p<0.035) (Table 4) 
 
Blood Pressure 
SBP, cSBP, cDBP, DBP, and MAP were not significantly different in either condition 
during or after sitting (Table 2 and 3). 
 
CD34+ CAC 
There was no significant interaction for CACs as a percentage of the parent population, 
and CACs per 500,000 events, nor was there a significant main effect of time or condition. 
(Figure 3).  
Figure 2. Changes in a) PWV from before (pre) and after (post) 3 hours of sitting. PWV 
significantly increases following sitting in both conditions (p<0.05). b) AIx before and after 
sitting in CON and CALF. AIx significantly decreases from 10 minutes to 90 minutes and 
stays depressed at 170 minutes in both conditions (p<0.05). # represents a significant effect of 
time (0<0.05). Different letters represent significantly different values at respective time 
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CD34+ CAC mRNA expression 
Expression of the angiogenic cytokine VEGF and the chemokine receptor CXCR4 
relative to GADP expression did not significantly change between conditions or across time for 
immunomagnetically separated CD34+ CACs (Figure 4).  
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Figure 3. Graph illustrating a) Percent change in CACs in CON vs. CALF and b) changes in 
CAC counts/500,000 from pre to post in CON and CALF. There were no significant 
condition, time or interaction effects. Error bars are represented as SD. CAC circulating 
angiogenic cells, CON control group, CALF calf raise group, SD standard deviation. 
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Figure 4. Gene expression of A) the angiogenic cytokine VEGF and B) the chemokine receptor CXCR4 did not change 
with sitting or not change with sitting or calf raises. mRNA is expressed without units relative to GADPH expression. There 
were no significant group, time or interaction effects. Error bars are represented as SD. VEGF vascular endothelial growth 
factor, CXCR4 CXC chemokine receptor-4, CAC circulating angiogenic cells, CON control group, CALF calf raise group, 
SD standard deviation.  
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Table 1. Baseline differences between hemodynamic measures in 
young healthy men and women 
   CON EXP P value ES 
SBP   116 (11) 117 (10) 0.227 -0.152 
DBP   70 (9) 70 (8) 0.758 0.041 
MAP   84 (10) 84 (7) 0.917 -0.015 
HR   66 (8) 64 (10) 0.140 0.267 
cSBP   102 (10) 103 (9) 0.404 -0.101 
cDBP   71 (9) 71 (7) 0.936 0.012 
Aix   9 (9) 9 (9) 0.817 -0.038 
Pf   26 (3) 27 (5) 0.450 -0.188 
Pb   12 (3) 13 (3) 0.963 -0.009 
PWV   5.3 (0.7) 5.4 (0.5) 0.640 -0.037 
Mean (SD). Exp experiemental, Con control, SBP systolic blood 
pressure, DBP diastolic blood pressure, MAP mean arterial 
pressure, HR heart rate, cSBP central systolic blood pressure, 
cDBP central diastolic blood pressure, AIx augmentation index, 
Pf pressure wave forwards, Pb pressure wave backwards 
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Table 2. Supine PWA measures at baseline vs. post 3-hours of sitting with and without calf raises on central hemodynamics 
Outcome        Interaction   Time   Leg   
      Pre Post P ES P ES P ES 
SBP Con   116 (11) 117 (11) 0.854 0.002 0.524 0.022 0.338 0.048 
  Calf   117 (10) 118 (12)             
DBP Con   70 (9) 72 (9) 0.947 <0.001 0.086 0.147 0.683 0.009 
  Calf   70 (8) 72 (8)             
MAP Con   84 (10) 85 (10) 0.601 0.015 0.382 0.041 0.649 0.011 
  Calf   84 (10) 85 (10)             
HR Con   66 (8) 63 (10) 0.288 0.059 0.012 0.290 0.187 0.090 
  Calf   64 (10) 62 (9)             
cSBP Con   102 (10) 101 (10) 0.812 0.003 0.554 0.019 0.590 0.016 
  Calf   103 (9) 102 (10)             
cDBP Con   71 (9) 73 (9) 0.732 0.006 0.064 0.169 0.589 0.016 
  Calf   71 (7) 72 (8)             
AIx Con   9 (9) 0 (10) 0.806 0.003 0.001 0.640 0.612 0.014 
  Calf   9 (9) 1 (10)             
Pf Con   26 (2) 26 (3) 0.733 0.006 0.394 0.038 0.378 0.041 
  Calf   27 (5) 26 (4)             
Pb Con   12 (3) 11 (2) 0.895 0.001 0.012 0.291 0.913 0.001 
  Calf   13 (3) 11 (2)             
Mean (SD), SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial pressure, HR heart rate, 
cSBP central systolic blood pressure, cDBP central diastolic blood pressure, AIx augmentation index, Pf pressure wave 
forwards, Pb pressure wave backwards 
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Table 3. PWA and HRV throughout a 3-hour bout of sitting with or without calf raises 
 
Measure  Time (min)    Interaction 
 
Time 
 
Condition   
      10 90 170   P ES P ES P ES 
SBP Con   110 (11) 110 (10) 111 (11)   0.531 0.068 0.725 0.035 0.668 0.010 
  Calf   111 (11) 110 (11) 110 (10)               
DBP Con   69 (8) 69 (8)  70 (8)   0.381 0.102 0.111 0.217 0.349 0.046 
  Calf   67(6) 69 (7) 69 (7)               
MAP Con   82 (9) 82 (8) 82 (9)   0.109 0.219 0.115 0.214 0.401 0.037 
  Calf   67 (6) 69 (7) 69 (7)               
HR Con   73 (10) 75 (11) 74 (11)   0.535 0.067 0.294 0.127 0.569 0.017 
  Calf   72 (10) 74 (11) 74 (13)               
cSBP Con   98 (10) 97 (9) 98 (11)   1.000 0.076 0.241 0.114 0.864 0.001 
  Calf   98 (10) 96 (9) 98 (8)               
cDBP Con   70 (8) 71 (8) 71 (8)   0.398 0.097 0.507 0.105 0.188 0.089 
  Calf   67 (7) 70 (8) 67 (16)               
Pf Con   25 (4) 25 (5) 23 (4)   0.405 0.102 0.086 0.242 0.631 0.012 
  Calf   26 (6) 24 (4) 24 (4)               
Pb Con   13 (2) 11 (2) 11 (2)   0.870 0.025 <0.001 0.495 0.771 0.005 
  Calf   13 (4) 11 (3) 11 (2)               
HF Con   28 (18) 19 (15) 18 (13   0.142 1.030 0.035 0.170 0.768 0.005 
  Calf   21 (14) 16 (13) 21 (15)               
LF Con   36 (16) 42 (22) 37 (15)   0.756 0.015 0.056 0.148 0.269 0.269 
  Calf   27 (12) 36 (14) 32 (12)               
Mean (SD), Con control SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial pressure, HR heart rate, 
cSBP central systolic blood pressure, cDBP central diastolic blood pressure, AIx augmentation index, Pf pressure wave forwards, 
Pb pressure wave backwards 
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Chapter V 
Discussion 
This study shows for the first time that an acute bout of 3 hours of sitting increases aortic 
AS and burden on the heart as indicated by increases in PWV. Despite increases in PWV, AIx 
decreased during sitting while RMSSD from HRV increased. Contrary to our hypothesis, sitting 
did not affect absolute or relative CAC counts. Additionally, intermittent calf raises were 
insufficient to prevent the changes in AS observed with acute inactivity and did not affect CACs.  
Cumulatively, these findings suggest: 1) a complex central hemodynamic response with different 
responses in AS versus arterial wave reflection, 2) that CD34+ CAC mobilization is not altered 
during 3 hours of sitting, and 3) that calf raises every 10 minutes do not appear to be a strong 
enough stimulus to alter central hemodynamics or circulating factors, contrary to previous work 
showing alterations at the local level. 
Arterial Stiffness 
This is the first study to our knowledge measuring the effects of an acute bout of 
prolonged sitting on PWV. We observed that PWV increased by 0.35m/s following 3 hours of 
sitting, which was statistically significant but falls below the 1.0 m/s that has been deemed 
clinically significant, at least chronically [10]. The chronic effects sitting are well demonstrated 
on CV risk and mortality, but their effects on AS are less prevalent. The best available 
comparison to our knowledge comes from data in older men showing that after adjustment for 
physical activity, each additional hour/week spent sitting over a 5-year period is associated with 
a faster increase in PWV (0.007 m/s [95% CI 0.001, 0.013]) [65]. The finding that chronic sitting 
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increases PWV along with acute increases in PWV during one bout of sitting implies that 
increased burden on the heart may contribute to increased risk of CVD. The aorta is the most 
proximal elastic tube that the heart “feels” during each beat. Therefore, repeated bouts of sitting 
resulting in increased aortic AS suggest repeated burden on the heart.  
Despite the increase in PWV, we found ~9% decrease in AIx during sitting which is 
indicative of decreased arterial wave reflection and also AS. The conflicting results of PWV and 
PWA may be a result of different theory and methodology behind PWV and PWA, which must 
be discussed to determine potential explanatory mechanisms. The expert consensus document on 
AS suggests that the methods of PWV and PWA incorporate differing levels of the arterial tree 
to different degrees [8]. PWV is a direct measurement of aortic stiffness and is considered the 
gold standard that corresponds to the accepted propagative model of the arterial system and is 
highly dependent on the elasticity of the aorta. Meanwhile, PWA is an indirect measure of AS 
calculated from forward and reflected pressure waves. The origin of these reflected pressure 
waves is a result of forward and reflected waves that incorporate many conduit arteries. These 
conduit arteries have greater smooth muscle content and vasomotor tone, which does impact AIx 
independently of PWV [66]. As such, the nervous system provides as one potential mediator. 
There was a trend for increasing RMSSD during sitting which suggests an increase in 
parasympathetic nervous system function. However, the peripheral vasculature is primarily 
innervated by the sympathetic nervous system. Both LF and HF frequency decreased, so the 
sympathetic branch likely had decreased innervation, which would be in agreement with the 
general convention that resting decreases sympathetic outflow. Furthermore, the forward and 
back ward pressure waves, which are related to the contractility of the heart and the location of 
reflected waves, respectively, both decreased during sitting. Together these findings suggest that 
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the decreased AIx may resonate from increased vasodilation which may be occurring as a result 
of decreased sympathetic outflow during sitting. Lastly, a 10 bpm increase in heart rate has been 
demonstrated to decrease absolute AIx by 4%, but there were no significant changes in HR 
during sitting thus eliminating this possibility [67].  In summary, these findings suggest that 
sitting promotes a complex central hemodynamic response that incorporates many heterogeneous 
regions of the arterial tree that are variably affected during sitting and potentially regulated by 
the ANS.  
 
Circulating Angiogenic Cells 
Moderate and vigorous intensity exercise mobilize CD34+ CACs in an intensity 
dependent manner, but the precise mechanisms are not clear [68] [69]. We hypothesized that 
increased shear stress during exercise was one potential mediator, the decrease in shear stress 
during sitting would elicit the opposite effect [23, 68, 69]. Interestingly, despite very different 
populations, baseline CAC counts are similar (after unit conversion) to reports in young active 
males with VO2max >50ml/kg/min in which counts were ~250 CD34+ events/1mL [58]. 
However, CAC mobilization do not appear to be affected by prolonged sitting as there was no 
change in absolute or relative CD34+ CAC counts. This was contrary to our hypothesis that 
sitting would decrease the release of CACs. Because this is the first study to our knowledge to 
assess the effects of an acute bout of sitting on CACs, comparisons to previous work are 
challenging. The closest comparison comes from a study on ten days of reduced physical activity 
which decreased CFU-CACs, but did not change CAC counts, which is agreement with our 
findings[7].  
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While exercise increases CAC counts and this change may be due to increases in shear 
stress, the decreases associated with sitting were likely not as large of a magnitude, albeit in the 
opposite direction. Blood flow and shear stress changes with exercise are sustained throughout 
the entirety of the bout. In our pilot data, calf raises did elicit considerable increased in shear 
stress, but these changes were transient and returned to resting values rapidly (within 1-2 
minutes). Additionally, sitting decrease blood flow in the legs, but the same has not been found 
systemically. It is likely that the changes in systemic flow after sitting or during calf raises were 
not strong enough to alter CAC mobilization[5]. However, activity or health status could be 
affecting baseline counts as others have reported a relationship between risk of CVD and 
decreasing CAC counts [70]. Therefore, the possibility of low CAC counts to begin with may 
have overshadowed the potential decrease observed from sitting. 
Functionally, mRNA analyses did not show any significant differences in expression of 
the chemokine receptor CXCR4 or the angiogenic cytokine VEGF, which are both expressed by 
CACs. Given the lack of change in counts, there may also be additional mechanisms that were 
not sufficiently targeted with this intervention. Specifically, hypoxia-inducible factor 1 (HIF-1) 
is a transcription factor expressed by bone marrow and CACs that is rapidly degraded under 
normoxic conditions[71]. On the contrary, under hypoxic conditions such as exercise, HIF-1 is 
not degraded and acts as a master regulator for genes related to proliferation, survival and 
mobilization such as stromal derived factor-1 (SDF-1), the chemokine receptor for CXCR4, 
VEGF, and erythropoietin[15, 72, 73]. Calf raises were unlikely to induce a large change in 
oxidative state in bone marrow or CACs; thus providing a possible explanation for the lack of 
changes in CAC count and function.  
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Calf Raises 
Previous evidence suggests that simple perturbations during sitting such as walking, 
fidgeting or standing can improve endothelial health in the popliteal or superficial femoral artery  
[12, 13, 38], however, these studies did not report changes in the arm, which is the generally 
accepted measure of endothelial health. In this study, we attempted to address this gap by 
utilizing regular muscular contractions (e.g. calf raises) to activate the muscle pump and increase 
venous return while examining clinically relevant measures of vascular health, albeit at a 
different segment of the arterial tree. Data suggests that despite the decrease in blood pooling, 
calf raises do not acutely affect aortic AS. Despite evidence demonstrating the benefits of 
fidgeting and walking on leg endothelial function, similar perturbations such as calf raises do not 
alter AS during sitting. This may be as a result of the fact that FMD is highly dependent on shear 
stress whereas, AS is only partially dependent on it and this varies depending on the location 
within the arterial tree [74]. Additionally, the changes from fidgeting and brief exercise were 
only seen in the legs and not the arms, which may mean that the change in blood flow and shear 
stress are not sufficient to affect the arterial tree overall, rather the legs are may be more sensitive 
to small increases in shear stress and that only monitoring the legs may lead to misleading 
conclusions. Here we show that while fidgeting may be sufficient to prevent decreases in leg 
health, such simple perturbations appear to be inadequate for inducing changes in variables 
related to overall CV health. 
Sitting Recommendations 
In terms of general guidelines for sitting, chronic sitters may prevent the long term 
detrimental effects of sitting by performing 60-75 minutes of moderate to vigorous activity per 
week [62]. While these guidelines should be heeded to prevent the effects of sitting, ACSM 
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guidelines recommending 150 minutes of moderate to vigorous physical activity should also be 
recommended to prevent other consequences of sedentary lifestyles [75].  Lastly, preliminary 
evidence on the acute effects of sitting suggest that interventions such as fidgeting, local heating, 
and intermittent exercise can prevent the detrimental changes in local blood flow associated with 
sitting, but these changes may not be generalized to systemic vascular health such as PWV. 
 
 
Limitations 
While we present several novel findings that expand our knowledge on the effects of an 
acute bout of sitting, there are limitations. This study included majority women (n=15) currently 
using birth control. The effects of estrogen levels on vascular health have mixed results [76, 77]. 
Use of contraception such as birth control was not a delimitation of this study, and the majority of 
women is this study reported either use of contraceptives that inhibited their ability to report their 
menstrual cycle. Although men and women differ in sex hormone levels which may affect basal 
counts of CACs, we did test the effects of sitting on men vs. women, on CAC counts and did not 
find any significant differences (data not shown).  Additionally, when participants were moved 
from seated to the supine position, a hemodynamic shift and changes in blood flow likely occurred 
that may have affected results. To limit these changes, participants were manually moved from 
position to position in 5-8 seconds to prevent an orthostatic challenge. Yet, it must be noted that 
because PWV and PWA were performed in the supine position, these hemodynamic shifts may 
have affected our results. Circulating CAC cell number and frequency were assessed from 
systemic changes and may not reflect events at endothelial tissue. Lastly, CACs are a rare cell sub 
type that resulted in very low mRNA yield, as a result, only two targets could be assessed.  
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Conclusions 
Prolonged sitting is still an emerging risk factor for the development of CVD. However, 
the precise mechanism explaining the effects of sitting remained in question, with many 
clinically relevant targets still unexamined. Here we show that sitting in may increase central 
burden on the heart, and that calf raises do not appear to clinically alter these changes. 
Furthermore, sitting does not induce changes in CAC counts or function. Because sitting confers 
increased risk of mortality, these findings suggest that increased burden on the heart due to 
increased aortic AS may be a contributing factor. Cumulatively, these findings suggest that 
sitting produces a detrimental vascular response from a systemic but not stem cell level that 
intermittent calf raises do not seem to effect, and that the nervous system likely plays a 
compensatory mechanistic role. 
 
Clinical Implications 
  Practically, these results add to the body of evidence regarding the effects of sitting. In 
terms of lifestyle interventions, ACSM guidelines of 150 minutes of moderate to vigorous 
physical activity are recommended for optimal health benefits; if these can’t be met current at 
least 60-75 minutes of moderate to vigorous activity can prevent the increased risks associated 
with sitting [62, 75].  Interventions while sitting lack longitudinal clinical evidence, but 
fidgeting, local heating, and intermittent exercise while sitting can prevent the detrimental 
changes in blood flow associated with sitting.  
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Figure S1. Gating Strategy and CD34 Purity 
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B) 
 
Fig S1. A) Gating strategy for CACs and purity of magnetic separation. Live cells were gated 
first.  Singlets were gated, followed by all mononuclear cells and a lymphocyte gate to capture 
CD34+ PBMCs. B) Flow cytometry data collected from magnetic isolation and subsequent 
staining with anti-CD34+ antibodies. Data represents positive fraction, negative fraction, and 
unseparated PBMCs from the same participant. 
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Figure S2. Example titration data for CD34 
 
 
 
 
 
Fig S2. Example titration data for CD34. Concentration with greatest signal to noise ratio was 
selected as optimal concentration. A-D) Samples were prepared using step wise increasing 
concentrations of anti-body stains from 0.5 to 1.0 to 2.5 to 5.0 µL. E) Overlaid histograms with 
0.5 in plum, 1.0 in green, 2.5 in blue, and 5.0 in gray.   
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Appendices 
Appendix A 
Department of Exercise and Sport Science 
Medical History Questionnaire Screening 
Subject:__________________________  Telephone:______________ 
Address:________________________________________________________________ 
Email:___________________________________  Age:______________________ 
Patient History 
1. How would you describe your general health at present?  YES NO 
2. Excellent______ Good_______ Fair______ Poor______ 
3. Do you have any health problems at the present time?  _____ _____ 
4. If yes, please describe:        
             
5. Have you ever been told you have heart trouble?   _____ _____ 
6. If yes, please describe:        
             
7. Do you ever get pain in your chest?     _____ _____ 
8. Do you ever feel light-headed or have you ever fainted?  _____ _____ 
9. If yes, please describe:        
             
10. Have you ever been told that you have high blood pressure? _____ _____ 
11. If yes, please describe:        
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12. Have you ever had difficulty breathing at rest or with exertion? _____ _____ 
13. If yes, please describe:        
             
14. Have you ever been treated for infectious mononucleosis, hepatitis, pneumonia, or 
another infectious disease during the past year?    _____ _____ 
15. If yes, name the disease:         
16. Have you ever been treated for or told you might have diabetes? _____ _____  
17. Have you ever been treated for low blood sugar?   _____ _____ 
18. Have you ever experienced heat stroke or heat exhaustion?  _____ _____ 
19. If yes, when?          
             
20. Are you now taking any pills, medications, or supplements? _____ _____ 
21. If yes, please list:         
             
22. Have you had any recent (within 1 year) difficulties with your: 
 a.  Feet        _____ _____ 
 b.  Legs        _____ _____ 
 c.  Back        _____ _____ 
Menstrual Cycle 
23. What was the start date of your most recent menstrual cycle? __________ 
Family History 
24. Has anyone in your family (grandparent, father, mother, and/or sibling) experienced 
any of the following? 
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 a.  Sudden death       _____ _____ 
 b.  Cardiac disease       _____ _____ 
 c.  Marfan’s syndrome      _____ _____ 
 
Bone and Joint History 
25. Have you ever been treated for Osgood-Schlatter’s disease?  _____ _____ 
26. Have you ever had any injury to your neck involving nerves or  
vertebrae?         _____ _____ 
27. Do you experience pain in your back?    _____ _____ 
28. Have you ever had an injury to your back?    _____ _____ 
29. If yes, did you seek the advice of a doctor?    _____ _____ 
30. Have you ever been told that you injured the ligaments or cartilage of either knee 
joint?          _____
 _____ 
31. Do you think you have a trick knee?     _____ _____ 
32. Do you have a pin, screw, or plate anywhere in your body as the result of bone or 
joint surgery that presently limits your physical capacity?  _____ ____ 
33. If yes, indicate where:          
 
Activity History 
34. During your early childhood (to age 12) would you say you were: 
 Very active ____ Quite active____ Moderately active____ Seldom active____ 
35. During your adolescent years (age 13-18) would you say you were: 
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 Very active ____ Quite active____ Moderately active____ Seldom active____ 
36. Did you participate in: 
Intramural high school sports?     _____ _____ 
Community sponsored sports?     _____ _____ 
Varsity high school sports?     _____ _____ 
Active family recreation?      _____ _____ 
37. Since leaving high school, how active have you been? 
 Very active ____ Quite active____  Active____  Inactive____ 
38. Have you previous participated in strength training   _____ _____ 
39. Do you participate in any moderate to vigorous activity at present? _____ _____ 
40. If yes, please list: 
Activity  Frequency   Duration  Intensity 
            
            
            
             
41. Whom shall we notify in case of emergency? 
 Name:            
 Phone: (Home)     (Work)     
 
Signature:        Date:     
 
 
50 
 
 
Appendix B 
 
GENDER: M  /  F
DOB: 
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Appendix C 
University of North Carolina at Chapel Hill 
Consent for Storing Biological Specimens Without Identifying Information 
_______________________________________________________________________ 
 
Consent Form Version Date: ______________ 
IRB Study # 16-3051 
Title of Study: Effects of Prolonged Sitting on Cerebral Perfusion and Executive Function 
Principal Investigator: Quentin Willey 
Principal Investigator Department: Exercise and Sport Science 
Principal Investigator Phone number: (919) 962-0396 
Principal Investigator Email Address: qwilley@live.unc.edu  
Co-Investigators: Erik Hanson, Claudio Battaglini, William Evans 
 
 
Faculty Advisor: Lee Stoner 
Faculty Advisor Contact Information: (919) 962-0534 
 
___________________________________________________________________________ 
 
What are some general things you should know about research? 
Research is designed to gain scientific information that may help other people in the future.  You 
may not receive any direct benefit from participating. There also may be risks. 
 
You may refuse to take part in research.  If you are a patient with an illness, you do not have to 
be in research in order to receive treatment. 
 
Details are discussed below.  It is important that you understand this information so that you can 
make an informed choice.  You will be given a copy of this consent form.  You should ask the 
researchers named above, or staff members who may assist them, any questions you have about 
this study at any time. 
 
What is the purpose of this specimen repository or “biobank?” 
Research with blood, tissue or body fluids (specimens) can help researchers understand how the 
human body works.  Research can also answer other questions by using specimens.  Researchers 
may develop new tests to find diseases, or new ways to treat diseases.  In the future, research 
may help to develop new products, such as drugs.  Specimens are commonly used for genetic 
research.  Sometimes researchers collect and store many specimens together and use them for 
different kinds of research, or share them with other scientists; this is called a specimen 
repository or “biobank.” 
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The purpose of this particular repository or biobank is to better understand the mechanisms 
altering vascular repair during sitting. This will include blood plasma or whole blood. Future 
research may be assessment of mRNA with sitting to assess potential changes in protein 
development during sitting.  
How will the specimens be collected? 
• Provide specific details about how the specimen will be collected, OR 
• if specimen already exists from previous clinical sources or research studies, inform 
subjects. 
What will happen to the specimens? 
Address specific areas about how the sample will be used and stored: 
• Provide a clear description of the operation of the specimen repository 
• Where will the specimen be stored? 
• When will the specimens be destroyed? 
• Inform subjects of conditions under which data and specimens will be released to other 
investigators.  
What are Genome Wide Association Studies (GWAS)? 
Delete if this does not apply to your study and you know data will never be submitted to GWAS 
The National Institutes of Health (NIH) has established a national database that will hold 
information from many individuals across the country, including medical information and 
genetic information.  Your blood and tissues contain genes which are made of DNA that is 
unique to you.  Access to this national database will be controlled and limited to other 
researchers. 
 
What are the possible benefits to you? 
Benefits to you are unlikely.  Studies that use specimens from this repository may provide 
additional information that will be helpful in understanding the effects of prolonged sitting.  
 
What are the possible risks or discomforts involved with the use of your specimens? 
Describe immediate and long-term social, physical, and psychological risks/discomforts related 
to the specimen collection and storage.  Address all risks that are applicable. 
• Unknown risk:  Subjects should be informed that there may be risks that at this time are 
unknown. 
• Physical risks: If new samples are being collected include the physical risk associated 
with the sample collection for research purposes. 
• In addition, use the following. 
Sometimes there are concerns, even if hypothetical, that people may find out things about you 
(for example, that your genes make you susceptible to a certain disease).  These concerns are 
minimized with this repository, because the specimens will not be able to be linked to your 
identity, so it will be impossible for anyone to know which sample came from you. 
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Will there be any cost to you for storage of the specimens? 
There will be no cost to you for the storage and use of the specimens for research purposes. 
 
Will you receive anything for the use of your specimens? 
 
You will not be receiving compensation for taking part in this study. 
 
 
Who owns the specimens? 
Insert any contract, grant or agreement language related to specimen ownership or modify the 
following boilerplate. 
 
Any blood, body fluids, or tissue specimens obtained for this purpose become the exclusive 
property of the University of North Carolina at Chapel Hill. This organization may retain, 
preserve or dispose of these specimens and may use these specimens for research that may result 
in commercial applications.  There are no plans to compensate you for any future commercial 
use of these specimens. 
 
How will information about you be protected? 
The researchers will not have any identifying information about you so there is no risk to your 
privacy. 
 
 
Will you receive study results of future research involving your specimens? 
Most research with your specimens is not expected to yield new information that would be 
meaningful to share with you personally.  In this case that would be impossible, because the 
researchers have no information that identifies you. 
 
Can you withdraw the specimen from this repository? 
You may not withdraw your specimen in the future because there are no identifiers on the 
specimen and the researchers will not know which specimen is yours. 
 
What will happen if you are injured by this research? 
Omit this section if the specimens have already been collected. 
All research involves a chance that something bad might happen to you.  This may include the 
risk of personal injury.  In spite of all safety measures, you might develop a reaction or injury 
from having your specimen collected.  If such problems occur, the researchers will help you get 
medical care, but any costs for the medical care will be billed to you and/or your insurance 
company.  The University of North Carolina at Chapel Hill has not set aside funds to pay you for 
any such reactions or injuries, or for the related medical care.  However, by signing this form, 
you do not give up any of your legal rights. 
 
Who is sponsoring this research? 
This research is funded by a Junior Faculty Grant from the University of North Carolina. This 
means that the research team is being paid by the sponsor for doing the study.  The researchers 
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do not, however, have a direct financial interest with the sponsor or in the final results of the 
study. 
 
 
 
What if you have questions about this research? 
You have the right to ask, and have answered, any questions you may have about this research. If 
you have questions, you should contact the researchers listed on the first page of this form. 
 
What if you have questions about your rights as a research subject? 
All research on human volunteers is reviewed by a committee that works to protect your rights 
and welfare.  If you have questions or concerns about your rights as a research subject you may 
contact, anonymously if you wish, the Institutional Review Board at 919-966-3113 or by e-mail 
to IRB_ subjects@unc.edu. 
 
Subject’s Agreement: 
 
I have read the information provided above. I have asked all the questions I have at this time.  I 
voluntarily agree to participate.  I agree to my specimen(s) being stored without identifying 
code(s). 
 
______________________________________________________ 
Signature of Research Subject 
 
____________________ 
Date 
 
______________________________________________________ 
Printed Name of Research Subject 
 
______________________________________________________ 
Signature of Research Team Member Obtaining Consent 
 
____________________ 
Date 
 
______________________________________________________ 
Printed Name of Research Team Member Obtaining Consent 
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Appendix D 
University of North Carolina at Chapel Hill 
Consent to Participate in a Research Study 
Adult Participants  
 
Consent Form Version Date: ______________ 
IRB Study # 16-3051 
Title of Study: Effects of Prolonged Sitting on Cerebral Perfusion and Executive Function 
Principal Investigator: Quentin Willey 
Principal Investigator Department: Exercise and Sport Science 
Principal Investigator Phone number: (919) 962-0396 
Principal Investigator Email Address: qwilley@live.unc.edu  
Co-Investigators: Erik Hanson, Claudio Battaglini, William Evans 
 
 
Faculty Advisor: Lee Stoner 
Faculty Advisor Contact Information: (919) 962-0534 
 
_________________________________________________________________ 
 
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  To join the study is voluntary. 
You may choose not to participate, or you may withdraw your consent to be in the study, for any 
reason, without penalty. 
 
Research studies are designed to obtain new knowledge. This new information may help people 
in the future.   You may not receive any direct benefit from being in the research study. There 
also may be risks to being in research studies. Deciding not to be in the study or leaving the 
study before it is done will not affect your relationship with the researcher, your health care 
provider, or the University of North Carolina-Chapel Hill. If you are a patient with an illness, 
you do not have to be in the research study in order to receive health care. 
 
Details about this study are discussed below.  It is important that you understand this information 
so that you can make an informed choice about being in this research study.  
 
You will be given a copy of this consent form.  You should ask the researchers named above, or 
staff members who may assist them, any questions you have about this study at any time. 
 
What is the purpose of this study? 
 
The purpose of the current study is to examine the acute effects of prolonged sitting on 
cardiovascular health and cognition. Findings from this study may identify a simple strategy for 
offsetting the negative consequences of sitting, and may contribute to public health policy 
pertaining to sedentary behavior. 
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You are being asked to be in this study because you are between the ages of 18-35, and are not 
engaging in 90 minutes of moderate intensity activity or 30 minutes of vigorous activity per 
week.  
 
Are there any reasons you should not be in this study? 
You should not be in this study if you are/have: 
• Diabetes 
• Heart Disease 
• Atherosclerosis 
• Arrhythmias 
• Taking medications known to affect cardiovascular function 
• Smoking cigarettes 
• Pregnant 
 
How many people will take part in this study? 
There will be approximately 20 people in this research study at UNC-Chapel Hill. 
 
How long will your part in this study last? 
Should you wish to participate in the study, you will be required to attend Fetzer Hall for three 
visits. These visits will include an initial 30 minute visit to familiarize you, followed by two 
additional 4 hour visits.  
 
What will happen if you take part in the study? 
During visit one, participants will report to the UNC EXSS Laboratory where we will discuss the 
study with you. You will be screened for participation in the study which will include a medical 
history questionnaire. You will be fitted for a small probe and a chair. You will also take a 
cognitive test 7 to 10 times or until your scores normalize. Lastly, you will sit while measurements 
are taken during which you perform several sets of 10 calf raises. 
During visits two and three a cannula, similar to an IV, will be inserted. You will lie for 20 minutes. 
After this, vascular health measures will be measured and 30mL of blood will be drawn. You will 
then be transferred to a sitting position, where you will remain for 180 minutes while watching a 
low-stimulus nature documentary. A probe will non-invasively measure brain blood flow 
continuously during this time, and after 10, 90 and 170 minutes of sitting, non-invasive vascular 
function and executive function will be measured. At 180 minutes, you will then be transferred to 
the supine position. Following 10 minutes of quiet rest, vascular health will be non-invasively 
measured again. Although you will use the restroom prior to sitting, if you need to use the restroom, 
this will be recorded, and you will be asked to repeat this movement for the subsequent visit. Visit 
two and three will be the same procedure, but you will be doing 10 calf raises to a metronome 
every 10 minutes in one of these visits.  
 
What are the possible benefits from being in this study? 
58 
 
Research is designed to benefit society by gaining new knowledge.  You will not benefit 
personally from being in this research study. 
  
What are the possible risks or discomforts involved from being in this study? 
While in this study, blood will be collected. This requires an initial needle stick which may be 
uncomfortable and could cause bruising.  
 
There may be uncommon or previously unknown risks. You should report any problems to the 
researcher. 
 
A Urine Pregnancy test provided by the study will be obtained for all women of child-bearing 
potential. 
 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might affect 
your willingness to continue your participation.  
 
How will information about you be protected? 
Your identity will be confidential and protected through the use of identification numbers. 
Additionally, all measurements will be collected in a private setting with access to the laboratory 
behind several secure doors. Identification numbers will be assigned to attached data and stored 
in a locked filing cabinet in the EORL, which only Quentin Willey and William Evans will have 
access to. Your identification number and associated data will only be accessible to the research 
team. All information uploaded to an external hard drive will be encrypted.  
Participants will not be identified in any report or publication about this study. Although every 
effort will be made to keep research records private, there may be times when federal or state law 
requires the disclosure of such records, including personal information.  This is very unlikely, 
but if disclosure is ever required, UNC-Chapel Hill will take steps allowable by law to protect 
the privacy of personal information.  In some cases, your information in this research study could 
be reviewed by representatives of the University, research sponsors, or government agencies (for 
example, the FDA) for purposes such as quality control or safety. 
 
What will happen if you are injured by this research? 
In the occurrence of a rare adverse event, all members of the research team are CPR/AED 
certified so that they can provide the proper care to the Participant. A member of the research 
team will be with the Participant the whole time while in the neuromuscular research lab and 1-2 
members of the research team will be present during each exercise test. If deemed necessary, 
emergency medical services will be contacted. 
 
All research involves a chance that something bad might happen to you.  This may include the 
risk of personal injury. In spite of all safety measures, you might develop a reaction or injury 
from being in this study. If such problems occur, the researchers will help you get medical care, 
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but any costs for the medical care will be billed to you and/or your insurance company. The 
University of North Carolina at Chapel Hill has not set aside funds to pay you for any such 
reactions or injuries, or for the related medical care. You do not give up any of your legal rights 
by signing this form. 
 
 
What if you want to stop before your part in the study is complete? 
 
You can withdraw from this study at any time, without penalty.  The investigators also have the 
right to stop your participation at any time. This could be because you have had an unexpected 
reaction, or have failed to follow instructions, or because the entire study has been stopped. 
 
Will you receive anything for being in this study? 
 
You will be receiving measures of cardiovascular health reports for taking part in this study. 
Otherwise, there will be no compensation for study participation 
 
Will it cost you anything to be in this study? 
If you enroll in this study, you will not have any associated costs. 
 
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this research. If 
you have questions about the study (including payments), complaints, concerns, or if a research-
related injury occurs, you should contact the researchers listed on the first page of this form. 
 
 
What if you have questions about your rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect your rights 
and welfare.  If you have questions or concerns about your rights as a research subject, or if you 
would like to obtain information or offer input, you may contact the Institutional Review Board 
at 919-966-3113 or by email to IRB_subjects@unc.edu. 
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Participant’s Agreement: 
 
I have read the information provided above.  I have asked all the questions I have at this time.  I 
voluntarily agree to participate in this research study. 
  
 
______________________________________________________ 
Signature of Research Participant 
 
____________________ 
Date 
 
______________________________________________________ 
Printed Name of Research Participant 
  
 
______________________________________________________ 
Signature of Research Team Member Obtaining Consent 
 
____________________ 
Date 
 
______________________________________________________ 
Printed Name of Research Team Member Obtaining Consent 
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Appendix E 
 
 
Subject ID _____ Date & Time____________ Fasted:  Y or N 
 
Time of Protein Ingestion: _________ Stress level 0 to 10 ____ 
 
Last Exercise Session: ________ Did you walk/run/bike to campus? ________  
 
 
 
Previous NIRS measures 
 
Upward distance (cm):____ Distance to the right of previous dot (cm):_____ 
 
Calf 
 
Leg used: L    or     R 
 
Dot on Tibia, Dot on medial malleolus 
 
Length from malleolus to bottom of stencil:  ______  
 
62 
 
Lines used (i.e. 1 or 10) : ______  
 
Side of line: toward high OR  low  
 
 
 
  
Electrocardiogram (ECG) and HRV 
 
Resting HR: _______ 
 
 
 
Metronome 
 
Set Metronome to 20 BPM every 10 minutes with buzzer 
 
Start time: ________ 
 
10___ 20___ 30___ 40___ 50___ 60___ 70___ 80___ 90___ 100__ 110__ 120__ 
 
130__ 140__ 150__ 160__ 170__ 
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Water 
 
Y N 
 
 
 
PWA 
Arm Side:  R  L 
 
PWV 
 
Carotid to Notch: __________cm  Notch to Top of Cuff: __________cm 
 
Femoral to cuff distance:  __________ cm 
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Baseline Variable 
Measure 
1 
Measure 
2 
Measure 
3 
Average 
of 2 
closest 
 
 
SBP     mmHg 
 
DBP     mmHg 
 MAP     BPM 
 HR     mmHg 
 
cSBP     mmHg 
 
cDBP     mmHg 
 
AIx     % 
 AIx @ 75      
 
Pf     mmHg 
 
Pb     mmHg 
 
RM     % 
 
PWV     m/s 
 Buckburg Index (SEVR)      
 
 
 
 
10 Variable 
Measure 
1 
Measure 
2 
Measure 
3 
Average 
of 2 
closest 
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SBP     mmHg 
 
DBP     mmHg 
 MAP     BPM 
 HR     mmHg 
 
cSBP     mmHg 
 
cDBP     mmHg 
 
AIx     % 
 AIx @ 75      
 
Pf     mmHg 
 
Pb     mmHg 
90 Variable 
Measure 
1 
Measure 
2 
Measure 
3 
Average 
of 2 
closest 
 
 
SBP     mmHg 
 
DBP     mmHg 
 MAP     BPM 
 
HR     mmHg 
 
cSBP     mmHg 
 
cDBP     mmHg 
 AIx     % 
 
AIx @ 75     
 
 
Pf     mmHg 
 
Pb     mmHg 
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Post Variable Measure 1 
Measure 
2 
Measure 
3 
Average 
of 2 
closest 
 
 
SBP     mmHg 
 
DBP     mmHg 
170 Variable 
Measure 
1 
Measure 
2 
Measure 
3 
Average 
of 2 
closest 
 
 
SBP     mmHg 
 
DBP     mmHg 
 MAP     BPM 
 
HR     mmHg 
 
cSBP     mmHg 
 
cDBP     mmHg 
 AIx     % 
 
AIx @ 75     
 
 
Pf     mmHg 
 
Pb     mmHg 
67 
 
 MAP     BPM 
 HR     mmHg 
 
cSBP     mmHg 
 
cDBP     mmHg 
 
AIx     % 
 AIx @ 75      
 
Pf     mmHg 
 
Pb     mmHg 
 
RM     % 
 
PWV     m/s 
 Buckburg Index (SEVR)      
 
 
 
 
 
 
 
HRV 
Variable Baseline 10 90 170 Post 
Mean RR      
STD RR      
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Stroop 
 
Variable Baseline 10 90 170 Post 
      
      
      
 
 
 
NIRS 
 
 
 
Blood Draw:  Pre time: ______ Post time: ______  
RMSSD      
HF (PNS)      
LF (SNS)      
Variable Baseline 10 90 170 Post 
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Appendix F 
SitR Familiarization 
 
Subject ID:  _____________ Date: _____________ Group: _________ 
 
Sex_____    Height (in/cm):_____/_____ Weight (lbs/kg):             /   
 
DOB: _____/________/_______  Age:____________ 
 
Time: _________ 
 
Urine Pregnancy Test: Y N 
 
Calculate and Give Protein Bars: Y N  
 
Screening, Consent and Medical Health History?        Y          N  
 
Randomization for Trial 1:  Raise OR Sit 
 
Chair Settings and Foot Placement 
 
70 
 
Height _____ (cm) Foot Placement ______ (cm)  
 
 
NIRS placement: Head 
 
Head Btwn eyes to occipital protuberance(cm): _____   10% of distance upwards (cm):____ 
 
Remeasure circumference ______ 5% of circum to Right of previous dot (cm):_____ 
 
Calf 
 
Malleolus to bottom line Tibia Length (cm): ____  
 
Lines used (i.e. 1 or 10) : ______  
 
Side of line: toward high OR  low  
 
 
Calf Practice 
 
Set Metronome to 20 BPM  Number of Practice sets _____  
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Stroop Practice 
 
Variable Trial 
1 
Trial 
2 
Trial 
3 
Trial 
4 
Trial 
5 
Trial 
6 
Trial 
7 
Trial 
8 
Trial 
9 
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Appendix G 
NIRS Optode Positions 
Cerebral:  
• Positioned at FP1 and FP2. 
• Place elatic band on head. 
• Measure Nz to Lz (approx. 36cm). 
• Mark distance of 10% upwards for Nz and Lz, these are Fpz and lz. 
• Move elastic band onto 10% line. 
• Measure circumference at 10% line (Fpz to lz, approx. 56 cm). 
• Measure and mark 5% of total circumference to left and right of Fpz and mark. 
• These are Fp1 (LEFT) and Fp2 (RIGHT). 
*Position probe 1 on Fp1 and probe 2 on Fp2. 
 
 
 
 
 
 
  
Gastrocnemius: 
• Positioned bilaterally on the medial gastrocnemius belly. 
• Ask patient to stand against bed and move on to tip toes (if possible) 
• Identify outer edge of muscle. Identify muscle belly and mark with dot. 
(This is just a preliminary identification to help with initial template placement.) 
 
• Ask participant to sit on a bench or table high enough that their leg is relaxed and 
suspended with approximately 90o between calf and thigh. 
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• Next, find the joint line between the femur and the tibia on the medial side. Follow that 
joint line by palpation laterally towards the patella. Mark the point at which the joint line 
and the patella first intersect with one dot. 
• Then, palpate the medial malleolus and find an approximate center and mark another dot. 
• Between the two dots described above, use a flexible meter stick to mark a straight line 
at the level of the gastrocnemius that if continued would intersect with each dot (Image 
A) 
• The line just drawn will be used as a base for the Calf ROI Stencil. Place the edge of the 
stencil on the line and make sure the slots of the stencil are parallel to the leg and on top 
of the medial gastrocnemius muscle belly (Image B). 
• Mark the bottom edge of the stencil by making a perpendicular line with the line already 
marked on the participant’s leg. Then, measure and record the distance (cm) between the 
line at the bottom of the stencil to the dot placed in the center of the medial malleolus. 
This distance will be used on this participant in future visits.  
• Finally, there will be 10 slots labeled on the stencil to mark where the NIRS probe will 
be secured. Two or three slots will need to be marked on the first visit in order to find the 
best NIRS placement. The best placement will be a relatively flat surface on the medial 
gastrocnemius. 
• Note which slots were marked, which slot mark will be used, and on which side of the 
mark the NIRS will be placed (+ = towards higher number or - towards lower number).  
• Remove any slot markings not being used from skin. 
*Position probe 3 on left and probe 4 on right. 
 
A.                                                      B.                                                        C. 
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